MGNX
MacroGenics, Inc.
$4.10
+0.74%
2026-08-21
About MacroGenics, Inc.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Key Fundamentals
Forward P/E
-3.35
EPS (TTM)
$-1.70
ROE
-140.3%
Revenue Growth (YoY)
47.6%
Profit Margin
-8.3%
Debt/Equity
172.23
Price/Book
12.63
Beta
1.22
Market Cap
$268.6M
Avg Volume (10D)
611K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$5.08
60D Low
$3.36
Avg Volume
859K
Latest Close
$4.10
Get breakout alerts for MGNX
Sign up for Breakout Scanner to receive daily notifications when MGNX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
MacroGenics, Inc. (MGNX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors MGNX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MGNX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.